We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
+47.39%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$2B
AUM Growth
+$348M
Cap. Flow
+$158M
Cap. Flow %
7.89%
Top 10 Hldgs %
49.36%
Holding
84
New
15
Increased
23
Reduced
21
Closed
18

Top Buys

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$49.2M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$40.6M
3
UTHR icon
United Therapeutics
UTHR
+$39.8M
4
CYTK icon
Cytokinetics
CYTK
+$36.5M
5
ABVX
Abivax
ABVX
+$32.5M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$68.5M
2
RNAM
Avidity Biosciences
RNAM
+$36.1M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$34M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$27.8M
5
ERAS icon
Erasca
ERAS
+$21.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.96%
2 Miscellaneous 3.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$44.6B
$195M 9.71%
2,000,000
– –
ERAS icon
2
Erasca
ERAS
$6.31B
$180M 9.01%
11,150,000
-1,850,000
-14% -$21.9M
IDYA icon
3
IDEAYA Biosciences
IDYA
$3.87B
$115M 5.74%
3,450,000
+325,000
+10% +$10.9M
PRAX icon
4
Praxis Precision Medicines
PRAX
$9.63B
$91.8M 4.58%
285,000
-90,000
-24% -$27.8M
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
$84.4M 4.21%
2,125,000
+1,925,000
+963% +$49.2M
TERN
6
DELISTED
Terns Pharmaceuticals
TERN
$79.1M 3.95%
1,500,000
+750,000
+100% +$30.8M
ABVX
7
Abivax
ABVX
$9.89B
$75.2M 3.75%
675,000
+275,000
+69% +$32.5M
TNGX icon
8
Tango Therapeutics
TNGX
$3.94B
$62.8M 3.13%
3,000,000
-1,200,000
-29% -$16.7M
CYTK icon
9
Cytokinetics
CYTK
$10B
$57.7M 2.88%
875,000
+575,000
+192% +$36.5M
OLMA icon
10
Olema Pharmaceuticals
OLMA
$899M
$47.8M 2.39%
3,208,875
– –
UTHR icon
11
United Therapeutics
UTHR
$22.1B
$47.4M 2.37%
+80,000
New +$39.8M
IMCR icon
12
Immunocore
IMCR
$1.89B
$45.2M 2.26%
1,500,000
+650,000
+76% +$21M
MDGL icon
13
Madrigal Pharmaceuticals
MDGL
$12.3B
$44.5M 2.22%
+85,000
New +$40.6M
RYTM icon
14
Rhythm Pharmaceuticals
RYTM
$7.38B
$39.1M 1.95%
450,000
+260,000
+137% +$25.3M
CGON icon
15
CG Oncology
CGON
$6.59B
$38.9M 1.94%
575,000
+375,000
+188% +$21.2M
MAZE
16
Maze Therapeutics
MAZE
$1.52B
$36.9M 1.84%
1,235,000
+285,000
+30% +$12.6M
BIIB icon
17
Biogen
BIIB
$32.3B
$36.7M 1.83%
200,000
– –
IRON icon
18
Disc Medicine
IRON
$3.07B
$35.8M 1.79%
560,000
+50,000
+10% +$3.47M
DNTH icon
19
Dianthus Therapeutics
DNTH
$5.92B
$33.6M 1.68%
400,000
+85,000
+27% +$4.92M
OCUL icon
20
Ocular Therapeutix
OCUL
$2.28B
$32.6M 1.63%
3,850,000
+350,000
+10% +$3.34M
TYRA icon
21
Tyra Biosciences
TYRA
$1.49B
$32.6M 1.63%
850,000
+640,000
+305% +$20.7M
TRVI icon
22
Trevi Therapeutics
TRVI
$2.39B
$28.6M 1.43%
2,400,000
+850,000
+55% +$9.52M
MLTX icon
23
MoonLake Immunotherapeutics
MLTX
$1.28B
$28M 1.4%
1,500,000
-250,000
-14% -$4.14M
IMVT icon
24
Immunovant
IMVT
$8.51B
$26.7M 1.33%
1,075,000
-300,000
-22% -$7.77M
TERN
25
CALL
DELISTED
Terns Pharmaceuticals
TERN
$26.4M 1.32%
+500,000
New +$20.5M
1
2 3 4

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q1 2026 Portfolio in Review

As of Q1 2026, Logos Global Management held 84 positions worth $2B, up 21% from $1.65B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Logos Global Management deployed $158M of net new capital in Q1 2026, opening 15 new positions and adding to 23 existing holdings. Its largest new stake was Madrigal Pharmaceuticals: 85,000 shares worth $44.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 91% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Praxis Precision Medicines, an estimated $27.8M trimmed.

  • Logos Global Management's largest Q1 2026 buy was Madrigal Pharmaceuticals: 85,000 shares worth $44.5M.
  • Logos Global Management added most to Centessa Pharmaceuticals in Q1 2026, an estimated $49.2M increase.
  • Logos Global Management's biggest Q1 2026 reduction was Praxis Precision Medicines, cutting an estimated $27.8M.
  • Logos Global Management fully exited Cidara Therapeutics in Q1 2026, selling an estimated $68.5M.
  • Logos Global Management's ten largest holdings make up 49% of its $2B portfolio in Q1 2026.
  • Logos Global Management opened 15 new positions and closed 18 in Q1 2026.
  • Logos Global Management's portfolio value rose 21% quarter-over-quarter to $2B.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.